New drug combo aims for long remission in untreated CLL patients

This study tests whether combining zanubrutinib (a BTK inhibitor) with rituximab (an antibody) can help control chronic lymphocytic leukemia or small lymphocytic lymphoma in people who have not had treatment before. About 60 participants will receive the combination, and researchers will measure how many achieve treatment-free remission for at least 6 months after stopping zanubrutinib. The goal is to see if this approach can keep the disease under control without needing ongoing therapy.